Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers

1:29:06
 
Share
 

Manage episode 317260049 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuvant, or perioperative immunotherapy in early-stage cancers, key trials and relevant endpoints, and evolving evidence supporting ICI use in different early-stage solid tumors, Implement best practices for multidisciplinary/interprofessional patient and tumor evaluation as well as coordination of care when managing patients with early-stage cancers, Integrate immunotherapies into individualized, multimodal treatment plans for appropriate patients with early-stage cancers in clinical practice or through clinical trial participation, Assess the risks and benefits associated with neoadjuvant/adjuvant/perioperative immunotherapy use to ensure safe, optimally selected, and appropriately timed delivery of systemic and local multimodal therapies to patients with early-stage solid tumors.

330 episodes